XNASEVAX
Market cap4mUSD
Dec 23, Last price
0.91USD
1D
-1.34%
1Q
-69.44%
IPO
-90.88%
Name
Evaxion Biotech A/S
Chart & Performance
P/E
—
P/S
67.28
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
7.32%
Rev. gr., 5y
%
Revenues
73k
Net income
-22m
L-4.51%
CFO
-18m
L-31.36%
Earnings
Mar 25, 2025
Profile
Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies for cancers, bacterial diseases, and viral infections. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase IIa trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy for the treatment of various cancers. Its programs also include EVX-B1, EVX-B2, and EVX-V1, which are vaccines that are in pre-clinical stage for the treatment of bacterial and viral diseases. The company was incorporated in 2008 and is headquartered in Hørsholm, Denmark.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | |
| Income | |||||||
Revenues | 73 | ||||||
Cost of revenue | 22,270 | 25,835 | 26,177 | ||||
Unusual Expense (Income) | |||||||
NOPBT | (22,197) | (25,835) | (26,177) | ||||
NOPBT Margin | |||||||
Operating Taxes | (791) | (772) | (178) | ||||
Tax Rate | |||||||
NOPAT | (21,406) | (25,063) | (25,999) | ||||
Net income | (22,125) -4.51% | (23,169) -5.56% | (24,532) 63.35% | ||||
Dividends | |||||||
Dividend yield | |||||||
Proceeds from repurchase of equity | 9,168 | 428 | 53,854 | ||||
BB yield | -489.11% | -10.21% | -625.05% | ||||
| Debt | |||||||
Debt current | 485 | 303 | 440 | ||||
Long-term debt | 12,607 | 4,207 | 5,770 | ||||
Deferred revenue | |||||||
Other long-term liabilities | 159 | 8,008 | 153 | ||||
Net debt | 7,480 | (8,883) | (25,956) | ||||
| Cash flow | |||||||
Cash from operating activities | (17,691) | (25,774) | (21,933) | ||||
CAPEX | (87) | (292) | (1,360) | ||||
Cash from investing activities | (93) | (268) | (1,330) | ||||
Cash from financing activities | 10,691 | 7,853 | 49,805 | ||||
FCF | (21,074) | (24,373) | (30,907) | ||||
| Balance | |||||||
Cash | 5,583 | 13,184 | 32,166 | ||||
Long term investments | 29 | 209 | |||||
Excess cash | 5,608 | 13,393 | 32,166 | ||||
Stockholders' equity | (105,844) | (72,424) | 32,437 | ||||
Invested Capital | 112,134 | 10,028 | (78,755) | ||||
ROIC | 72.94% | 66.04% | |||||
ROCE | 41.41% | ||||||
| EV | |||||||
Common stock shares outstanding | 2,734 | 2,364 | 1,949 | ||||
Price | 0.69 -61.37% | 1.78 -59.84% | 4.42 | ||||
Market cap | 1,874 -55.33% | 4,196 -51.30% | 8,616 | ||||
EV | 9,354 | (4,687) | (17,340) | ||||
EBITDA | (21,582) | (25,264) | (25,833) | ||||
EV/EBITDA | 0.19 | 0.67 | |||||
Interest | 897 | 1,508 | 915 | ||||
Interest/NOPBT | |||||||